UNSPSC 51172019: Cyclobutyrol sodium

This classification denotes the sodium form of a cholagogue or choleretic agent with the molecular formula C10H18O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8T4L120N6M, chemically known as cyclohexaneacetic acid, alpha-ethyl-1-hydroxy- but more generally known as cyclobutyrol, which bears US NIH Compound Identifier 72065. European Medicines Agency schedules Cyclobutyrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06851MIG.

UNSPSC 51172019 Cyclobutyrol sodium is a Commodity code with minimal recent state and local procurement activity explicitly tied to the chemical itself. The three most recent opportunities posted under or near this code span specimen collection and drug testing services, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals—none of which align closely with procurement of cyclobutyrol sodium as a discrete input material. The specimen collection RFP from Collin County Community Supervision and Corrections Department involves immunoassay screening and confirmatory testing methodologies but does not specify chemical reagents or cyclobutyrol sodium by name. The Texas Health and Human Services Commission RFI on therapeutic pharmacy initiatives and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic pharmaceuticals and OTC products address finished pharmaceutical products and supply-chain logistics, not raw chemical components. This mismatch suggests that cyclobutyrol sodium, if procured by state and local entities, is typically bundled within service contracts or purchased through pharmaceutical supply channels rather than solicited as a standalone commodity.

Recent activity shows no direct state or local RFPs, RFQs, or ITBs naming cyclobutyrol sodium as a line-item procurement. The issuing bodies with recent relevant postings—Collin County in Texas, Texas HHS, and the Minnesota Department of Administration—are pursuing drug testing, pharmacy benefit management, and generic pharmaceutical aggregation, respectively. Geographic activity centers on Texas and Minnesota, but neither jurisdiction has posted an explicit solicitation for cyclobutyrol sodium as a chemical input. If this code experiences procurement volume, it likely flows through cooperative purchasing vehicles, state master agreements for laboratory chemicals, or embedded procurement within service delivery contracts rather than through visible standalone competitive solicitations. Firms pursuing opportunities under this code should monitor cooperative purchasing platforms and state chemistry supply schedules, as direct-to-government demand for this chemical appears limited or absorbed into larger service-delivery frameworks.